0 56

Cited 3 times in

Low-dose mycophenolate mofetil in tablet form or capsule form combined with tacrolimus in the early period after kidney transplantation: a prospective randomized trial

Authors
 Su Lee  ;  Chan-Duck Kim  ;  Kyu Huh  ;  Baik-Hwan Cho  ;  Man Ju  ;  Dong Lee  ;  Hong Cho  ;  Jong-Won Park  ;  Jung Lee  ;  Samuel Lee  ;  Byung So  ;  Chang-Kwon Oh  ;  Yu Kim 
Citation
 Clinical Nephrology, Vol.86(12) : 319-327, 2016 
Journal Title
 Clinical Nephrology 
ISSN
 0301-0430 
Issue Date
2016
Abstract
AIMS: The tablet form (500 mg) of mycophenolate mofetil (MMF) provides more convenience of taking drugs and cost-effectiveness than the capsule form (250 mg). We examined the efficacy and safety of MMF in its different forms combined with tacrolimus in kidney transplant recipients. METHODS: This multicenter, 26-week, randomized trial was performed to compare the efficacy and safety of the tablet form of MMF versus the capsule form of MMF in 156 kidney transplant recipients. Allograft function, the incidence of efficacy failure (biopsy-proven acute rejection (BPAR), death, graft loss, or loss to follow-up), and adverse events were compared. RESULTS: The mean dose (mg/day) of MMF at 26 weeks was comparable: 1,052.6 ± 194.2 in the tablet group vs. 1,155.6 ± 298.1 in the capsule group (p = 0.063). Trough levels of tacrolimus at 26 weeks were comparable. The mean estimated glomerular filtration rate of the tablet group at 26 weeks post-transplant was not inferior to that of the capsule group. The incidence of efficacy failure was similar in the two groups: tablet group, 5.2% and capsule group, 7.7% (difference -2.5%; 95% confidence interval -5.22 - 10.21%). The incidence of BPAR until 26 weeks post-transplant in the tablet group was 3.9%, compared to 7.7% in the capsule group (p = 0.346). There was no significant difference in the incidence of discontinuations and serious adverse events between the groups. CONCLUSION: Low-dose MMF in tablet form combined with tacrolimus can be considered as an efficacious and safe immunosuppressive regimen in the early period after kidney transplantation.?
Full Text
https://www.dustri.com/nc/article-response-page.html?artId=14894&doi=
DOI
10.5414/CN108945
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers
Yonsei Authors
김유선(Kim, Yu Seun) ORCID logo https://orcid.org/0000-0002-5105-1567
주만기(Joo, Man Ki)
허규하(Huh, Kyu Ha) ORCID logo https://orcid.org/0000-0003-1364-6989
Export
RIS (EndNote)
XLS (Excel)
XML
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/152692
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse